Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial

Despite significant advances in the medical and device-based management of patients with heart failure (HF) with reduced ejection fraction (HFrEF), risk for adverse outcomes remains high in these patients, particularly after a recent decompensation.1,2 Risk models may inform the assessment of prognosis, planning of new trials, and clinical management decisions and treatment selection, particularly when there is evidence of a differential benefit of therapies aligned with baseline risk3 or clinical phenotype (ie, baseline characteristics).

Source: Journal of Cardiac Failure - June 30, 2021 Category: Cardiology Authors: Robert J. Mentz, Hillary Mulder, Arend Mosterd, Nancy K. Sweitzer, Michele senni, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Burkert Pieske, Piotr Ponikowski, Adriaan A. Voors, Kevin J. Anstrom, Paul W. Armstrong, Christopher M. O'connor, Adrian Source Type: research